FR2750866B1 - Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire - Google Patents

Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Info

Publication number
FR2750866B1
FR2750866B1 FR9608243A FR9608243A FR2750866B1 FR 2750866 B1 FR2750866 B1 FR 2750866B1 FR 9608243 A FR9608243 A FR 9608243A FR 9608243 A FR9608243 A FR 9608243A FR 2750866 B1 FR2750866 B1 FR 2750866B1
Authority
FR
France
Prior art keywords
avian
infectious laryngotracheitis
laryngotracheitis virus
living vaccine
recombinant living
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9608243A
Other languages
English (en)
French (fr)
Other versions
FR2750866A1 (fr
Inventor
Jean Christophe Franc Audonnet
Michel Joseph Marie Bublot
Michel Emile Albert Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Rhone Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux SA filed Critical Rhone Merieux SA
Priority to FR9608243A priority Critical patent/FR2750866B1/fr
Priority to MA24675A priority patent/MA24222A1/fr
Priority to AU34487/97A priority patent/AU739374B2/en
Priority to PCT/FR1997/001138 priority patent/WO1997049826A1/fr
Priority to EP97930591A priority patent/EP0914458A1/fr
Priority to ZA975618A priority patent/ZA975618B/xx
Priority to JP10502456A priority patent/JP2000512844A/ja
Priority to TNTNSN97109A priority patent/TNSN97109A1/fr
Priority to ARP970102799A priority patent/AR008620A1/es
Priority to IDP972222A priority patent/ID18351A/id
Priority to PE1997000548A priority patent/PE52599A1/es
Priority to CO97036155A priority patent/CO4700303A1/es
Publication of FR2750866A1 publication Critical patent/FR2750866A1/fr
Application granted granted Critical
Publication of FR2750866B1 publication Critical patent/FR2750866B1/fr
Priority to US09/219,932 priority patent/US6153199A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9608243A 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire Expired - Lifetime FR2750866B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
MA24675A MA24222A1 (fr) 1996-06-27 1997-06-23 Vaccin vivant recombinant aviaire utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
TNTNSN97109A TNSN97109A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP97930591A EP0914458A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
ZA975618A ZA975618B (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using as vector the avian infectious laryngotrachetis virus
JP10502456A JP2000512844A (ja) 1996-06-27 1997-06-25 ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン
AU34487/97A AU739374B2 (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
ARP970102799A AR008620A1 (es) 1996-06-27 1997-06-25 Vacuna viva recombinante, fragmento de adn y virus iltv que la componen
PCT/FR1997/001138 WO1997049826A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
IDP972222A ID18351A (id) 1996-06-27 1997-06-26 Vaksin hidup rekombinan avian, yang sebagai vektor menggunakan virus laringotracheitis menular avian
PE1997000548A PE52599A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa
CO97036155A CO4700303A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria
US09/219,932 US6153199A (en) 1996-06-27 1998-12-23 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (2)

Publication Number Publication Date
FR2750866A1 FR2750866A1 (fr) 1998-01-16
FR2750866B1 true FR2750866B1 (fr) 1998-11-27

Family

ID=9493649

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9608243A Expired - Lifetime FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Country Status (13)

Country Link
US (1) US6153199A (enExample)
EP (1) EP0914458A1 (enExample)
JP (1) JP2000512844A (enExample)
AR (1) AR008620A1 (enExample)
AU (1) AU739374B2 (enExample)
CO (1) CO4700303A1 (enExample)
FR (1) FR2750866B1 (enExample)
ID (1) ID18351A (enExample)
MA (1) MA24222A1 (enExample)
PE (1) PE52599A1 (enExample)
TN (1) TNSN97109A1 (enExample)
WO (1) WO1997049826A1 (enExample)
ZA (1) ZA975618B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US6632664B1 (en) 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
JP2002356441A (ja) * 2001-03-15 2002-12-13 Akzo Nobel Nv 組換え伝染性喉頭気管炎ウイルスワクチン
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
EP2022799A2 (en) 2001-11-16 2009-02-11 Biogen Idec Inc. Polycistronic expression of antibodies
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
ATE510928T1 (de) 2004-02-19 2011-06-15 Univ Alberta Leptinpromotor-polymorphismen und verwendungen davon
HRP20100314T1 (hr) 2005-04-25 2010-08-31 Merial Ltd. Cjepivo protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
BR112013002525A2 (pt) * 2010-08-02 2016-05-31 Univ Georgia vírus da laringotraqueíte infecciosa (iltv) modificado e usos do mesmo
CN103269714B (zh) 2010-08-31 2016-06-29 梅里亚有限公司 以新城疫病毒为载体的疱疹病毒疫苗
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
ES2626297T3 (es) 2011-08-12 2017-07-24 Merial, Inc. Preservación asistida por vacío de productos biológicos, en particular de vacunas
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
WO2014145712A1 (en) 2013-03-15 2014-09-18 Cardiomems, Inc. Methods for the treatment of cardiovascular conditions
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
DK3313864T3 (da) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002802A2 (en) * 1988-09-13 1990-03-22 Institute For Animal Health Limited Viral nucleotide sequences
WO1992003554A1 (en) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
WO1993025655A1 (en) * 1992-06-12 1993-12-23 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric
WO1996000791A1 (en) * 1994-06-30 1996-01-11 The Board Of Trustees Of The University Of Illinois Recombinant infectious laryngotracheitis virus and vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JP3964458B2 (ja) * 1995-03-23 2007-08-22 シェリング−プロウ・リミテッド 組換え型伝染性喉頭気管炎ウイルスおよびその使用

Also Published As

Publication number Publication date
CO4700303A1 (es) 1998-12-29
FR2750866A1 (fr) 1998-01-16
WO1997049826A1 (fr) 1997-12-31
AU3448797A (en) 1998-01-14
AR008620A1 (es) 2000-02-09
AU739374B2 (en) 2001-10-11
ID18351A (id) 1998-04-02
EP0914458A1 (fr) 1999-05-12
TNSN97109A1 (fr) 2005-03-15
JP2000512844A (ja) 2000-10-03
PE52599A1 (es) 1999-07-16
US6153199A (en) 2000-11-28
MA24222A1 (fr) 1997-12-31
ZA975618B (en) 1998-12-28

Similar Documents

Publication Publication Date Title
FR2750866B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2757061B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2728795B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
LU91327I2 (fr) Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DE69923434D1 (de) Adjuvierte rekombinante Lebendimpfstoffe gegen Influenza- oder Herpesviren
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
FR2750865B1 (fr) Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
ATE367442T1 (de) Newcastle-krankheitsvirus infektiöser klone, impfstoffe und diagnosetest
DK0870508T3 (da) Influenzavaccine
GB9811433D0 (en) Virus vaccine
EP1267626A4 (en) EXPRESSION SYSTEMS FOR RECOMBINANT PARA INFLUENZA VIRUSES AND VACCINE
DE60009609D1 (de) Abgasemissionsregeleinrichtung
DE69533305D1 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DE69839169D1 (de) Aus infektiöser cDNA gewonnene rekombinate YF Viren-Impfstoffe
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
BR9712067A (pt) Pept¡dios imunog-nicos de v¡rus da doen-a de febre aftosa
GB0100067D0 (en) Diesel exhaust system including NOx trap
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
DE60042130D1 (de) Neue antigene hev-peptide und methoden
IL143149A0 (en) Stable, attenuated rabies virus mutants and live vaccines thereof
AU5098700A (en) Dna vaccine for protecting an avian against infectious bursal disease virus

Legal Events

Date Code Title Description
CD Change of name or company name
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 20